GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.
Neogenix has developed an ELISA serum biomarker using, NPC-1C, its novel, proprietary chimeric antibody that selectively targets pancreatic and colorectal cancer. The prospective study, being conducted at Conemaugh Cancer Center, in Johnstown, PA, provides for the evaluation of blood serum samples from patients confirmed with pancreatic or colon cancer. Preliminary results demonstrate the Neogenix biomarker assay’s ability to differentiate between blood serum of healthy donors and that of patients with colorectal or pancreatic cancer. In addition, the results of the NPC-1C biomarker test indicate superior sensitivity as compared to commercially available CEA and CA19-9 assays. A complete data set will be presented at the ASCO Meeting.
"We are very excited about the study results which hold promise for the early detection of these devastating diseases. These tests could provide a real hope for patients by enabling early intervention and substantially improved clinical outcome,” says Philip M. Arlen, M.D, President and CEO of Neogenix Oncology.
Poster Presentation Information:
Abstract Title: Diagnostic/prognostic utility of a new serum biomarker ELISA for colorectal and pancreatic cancers.
Poster Session Date/Time: October 19, 2010, 12:35-2:00pm and 6:00-7:00pm
Permanent Abstract ID: 102
Location: Poster Board A45
The full abstract can be accessed through the ASCO website and the Neogenix Oncology website, www.neogenix.com. The complete study presentation poster will also be available on the Neogenix website, following the presentation.
About Neogenix Oncology
Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NPC-1C antibody in patients with metastatic pancreatic and colorectal cancer.
Forward Looking Statements
Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company’s SEC reports, including the company’s Form 10 and quarterly reports on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.